Avacta Appoints Therapeutics Chief Development Officer
Avacta has appointed Neil Bell, a highly experienced pharmaceutical and [...]
Horizon Discovery licenses CHOSOURCE platform to TrueBinding for development and commercialization of multiple biotherapeutics
TrueBinding signs multi-product commercial-use license to develop stable, antibody-expressing cell [...]
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy
Collaboration to develop stem cell therapies for COVID-19 and future [...]
Adaptate Biotherapeutics establishes Scientific Advisory Board with Professor Adrian Hayday as Chair
Professor Gillian Griffiths, Dr John Haurum, Dr Jessica Strid and [...]
Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test
Avacta to begin clinical validation of the high throughput COVID-19 [...]
Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation
· Partnership awarded Innovate UK Knowledge Transfer Partnership grant · Dr. John McGrath [...]
Cobra Biologics delivers final plasmids for production of CG01 in CombiGene’s epilepsy project
Further milestone paves the way for production of novel gene [...]
Avacta and Integumen plc collaborate for detection of SARS-COV-2 coronavirus in waste water
Partnership to evaluate the use of Affimer reagents to detect [...]
Spirea completes seed funding round to develop the next generation of antibody drug conjugate therapeutics
Spirea, a spin-out from the University of Cambridge, has developed [...]
LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector
London and Oxford, UK, 09 July 2020: Today, LGC announced [...]